Allogene Therapeutics (ALLO) Gains from Investment Securities (2019 - 2025)
Historic Gains from Investment Securities for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$315000.0.
- Allogene Therapeutics' Gains from Investment Securities rose 9475.0% to -$315000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $500000.0, marking a year-over-year increase of 2224.94%. This contributed to the annual value of -$4.3 million for FY2024, which is 16112.86% down from last year.
- Per Allogene Therapeutics' latest filing, its Gains from Investment Securities stood at -$315000.0 for Q3 2025, which was up 9475.0% from $1.9 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Gains from Investment Securities peaked at $28.2 million during Q2 2022, and registered a low of -$6.0 million during Q3 2024.
- Its 5-year average for Gains from Investment Securities is $4.0 million, with a median of $2.2 million in 2024.
- In the last 5 years, Allogene Therapeutics' Gains from Investment Securities surged by 2786140.35% in 2021 and then plummeted by 30373.51% in 2024.
- Quarter analysis of 5 years shows Allogene Therapeutics' Gains from Investment Securities stood at $4.1 million in 2021, then surged by 582.13% to $28.2 million in 2022, then tumbled by 85.84% to $4.0 million in 2023, then tumbled by 117.2% to -$688000.0 in 2024, then surged by 54.22% to -$315000.0 in 2025.
- Its last three reported values are -$315000.0 in Q3 2025, $1.9 million for Q2 2025, and -$425000.0 during Q1 2025.